Emerging safety issues in alemtuzumab-treated MS patients

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)1206-1208
Number of pages3
JournalMultiple Sclerosis Journal
Volume25
Issue number9
DOIs
Publication statusPublished - 1 Aug 2019

Cite this

@article{0d6ec5121f4a4de6ae2de2ff07bcdc07,
title = "Emerging safety issues in alemtuzumab-treated MS patients",
author = "Joep Killestein and {van Oosten}, Bob",
year = "2019",
month = "8",
day = "1",
doi = "10.1177/1352458519851219",
language = "English",
volume = "25",
pages = "1206--1208",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "9",

}

Emerging safety issues in alemtuzumab-treated MS patients. / Killestein, Joep; van Oosten, Bob.

In: Multiple Sclerosis Journal, Vol. 25, No. 9, 01.08.2019, p. 1206-1208.

Research output: Contribution to journalEditorialAcademicpeer-review

TY - JOUR

T1 - Emerging safety issues in alemtuzumab-treated MS patients

AU - Killestein, Joep

AU - van Oosten, Bob

PY - 2019/8/1

Y1 - 2019/8/1

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85070893418&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31368417

U2 - 10.1177/1352458519851219

DO - 10.1177/1352458519851219

M3 - Editorial

VL - 25

SP - 1206

EP - 1208

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 9

ER -